Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: A randomized crossover study

I. Wen Wu, Kuang Hung Hsu, Chio Yin Sun, Chi Jen Tsai, Mai-Szu Wu, Chin Chan Lee

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background. Indoxyl sulfate (IS) suppresses erythropoietin (EPO) activity and exerts renal damage. The oral adsorbent AST-120 reduces IS load and has antioxidant and renoprotective properties; however, its roles in the treatment of anemia remain unclear in chronic kidney disease (CKD) patients. Methods. Fifty-one Stage 5 predialysis CKD patients with hemoglobin

Original languageEnglish
Pages (from-to)1719-1727
Number of pages9
JournalNephrology Dialysis Transplantation
Volume29
Issue number9
DOIs
Publication statusPublished - 2014

Keywords

  • Anemia
  • Carbonaceous adsorbents
  • Chronic kidney disease
  • Uremic toxins

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Medicine(all)

Fingerprint Dive into the research topics of 'Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: A randomized crossover study'. Together they form a unique fingerprint.

  • Cite this